Hemostatic abnormalities in patients with thrombotic complications on maintenance hemodialysis.
Before hemodialysis (HD), plasma levels of tissue factor (TF), free-TF pathway inhibitor (TFPI) and thrombomodulin (TM) were significantly higher in patients with HD than in healthy volunteers. Plasma levels of (T-F) TFPI and plasmin plasmin inhibitor complex (PPIC) were significantly higher in patients with HD than in healthy volunteers. During HD, plasma levels of TF and (T-F) TFPI were not significantly increased, but plasma levels of total TFPI and free TFPI at 1 hour after and at the end of HD were significantly increased, compared with levels before start of HD. Plasma level of PPIC 1 hour after start of HD was significantly higher than before start of HD, and plasma levels of thrombin antithrombin complex (TAT), PPIC, D-dimer, TM, and protein C (PC) at the end of HD were significantly higher than before start of HD. In patients with thrombosis complications, plasma TF levels were significantly higher than in patients without thrombotic complications during HD. Plasma levels of PC were significantly lower in patients with thrombotic complications than in patients without thrombotic complications. There was no significant difference between both groups during HD in hemostatic parameters, with the exception of TF and PC. Hemostatic abnormalities existed in patients with HD; especially, increased TF and decreased PC might cause thrombotic complications.
Inoue
A
A
Second Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Japan.
Wada
H
H
Takagi
M
M
Yamamuro
M
M
Mukai
K
K
Nakasaki
T
T
Shimura
M
M
Hiyoyama
K
K
Deguchi
H
H
Gabazza
E C
EC
Mori
Y
Y
Nishikawa
M
M
Deguchi
K
K
Shiku
H
H
D000933:Antifibrinolytic Agents / Q000097:blood* / Q000378:metabolism*; D000990:Antithrombin III / Q000032:analysis; D015415:Biomarkers / Q000097:blood; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005341:Fibrinolysin / Q000378:metabolism*; D006487:Hemostasis; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000032:analysis; D012016:Reference Values; D006435:Renal Dialysis / Q000009:adverse effects*; D018180:Thrombomodulin / Q000097:blood*; D013925:Thromboplastin / Q000032:analysis*; D013927:Thrombosis / Q000097:blood* / Q000209:etiology*; D000979:alpha-2-Antiplasmin
D000933:Antifibrinolytic Agents; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D008074:Lipoproteins; D018180:Thrombomodulin; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C051928:lipoprotein-associated coagulation inhibitor; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D013925:Thromboplastin; D010447:Peptide Hydrolases; D005341:Fibrinolysin